By Christian Moess Laursen
GSK said it has bought Aiolos Bio, a biopharmaceutical company focused on patients with respiratory and inflammatory conditions, for an upfront consideration of $1.0 billion, with the potential for an additional $400 million.
Write to Christian Moess Laursen at christian.moess@wsj.com
